Evidence map›Paper›PMID 17925034›Full record

ArticleBreast cancer research : BCR2007

Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling.

Ana Quaglino, Carolina Schere-Levy, Leonardo Romorini, Roberto P Meiss, Edith C Kordon

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. LIF-ting Hippo averts metastasis.Nature medicine · 2012
    Article
  13. LIF-dependent signaling: new pieces in the Lego.Stem cell reviews and reports · 2012
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Ana QuaglinoIFIBYNE (CONICET), Facultad de Ciencias Exactas y Naturales, University of Buenos Aires, Argentina.
Carolina Schere-Levy
Leonardo Romorini
Roberto P Meiss
Edith C Kordon
Academia Nacional de Medicina · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARFundación Ciencias Exactas y Naturales · ARUniversity of Buenos Aires · AR

Funding

Tumor progression and apoptosis in mouse mammary glandR01TW006212 · FIC · NATIONAL ACADEMY OF MEDICINE · PI KORDON, EDITH C · 2002 to 2006
$254k
FIC NIH HHS R01 TW006212FIC NIH HHS R01TW006212
6 · The paper itself

Abstract

introductionIt has been demonstrated that leukemia inhibitory factor (LIF) induces epithelium apoptosis through Stat3 activation during mouse mammary gland involution. In contrast, it has been shown that this transcription factor is commonly activated in breast cancer cells, although what causes this effect remains unknown. Here we have tested the hypothesis that locally produced LIF can be responsible for Stat3 activation in mouse mammary tumors.

methodsThe studies were performed in different tumorigenic and non-tumorigenic mammary cells. The expression of LIF and LIF receptor was tested by RT-PCR analysis. In tumors, LIF and Stat3 proteins were analyzed by immunohistochemistry, whereas Stat3 and extracellular signal-regulated kinase (ERK)1/2 expression and phosphorylation were studied by Western blot analysis. A LIF-specific blocking antibody was used to determine whether this cytokine was responsible for Stat3 phosphorylation induced by conditioned medium. Specific pharmacological inhibitors (PD98059 and Stat3ip) that affect ERK1/2 and Stat3 activation were used to study their involvement in LIF-induced effects. To analyze cell survival, assays with crystal violet were performed.

resultsHigh levels of LIF expression and activated Stat3 were found in mammary tumors growing in vivo and in their primary cultures. We found a single mouse mammary tumor cell line, LM3, that showed low levels of activated Stat3. Incidentally, these cells also showed very little expression of LIF receptor. This suggested that autocrine/paracrine LIF would be responsible for Stat3 activation in mouse mammary tumors. This hypothesis was confirmed by the ability of conditioned medium of mammary tumor primary cultures to induce Stat3 phosphorylation, activity that was prevented by pretreatment with LIF-blocking antibody. Besides, we found that LIF increased tumor cell viability. Interestingly, blocking Stat3 activation enhanced this effect in mammary tumor cells.

conclusionLIF is overexpressed in mouse mammary tumors, where it acts as the main Stat3 activator. Interestingly, the positive LIF effect on tumor cell viability is not dependent on Stat3 activation, which inhibits tumor cell survival as it does in normal mammary epithelium.

Indexed as

Signal TransductionAnimalsBlotting, WesternCell SurvivalFemaleFluorescent Antibody TechniqueImmunoprecipitationLeukemia Inhibitory FactorLeukemia Inhibitory Factor Receptor alpha SubunitMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PhosphorylationReverse Transcriptase Polymerase Chain ReactionLeukemia Inhibitory FactorLeukemia Inhibitory Factor Receptor alpha SubunitLif protein, mouseLifr protein, mouseMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3RNA, MessengerStat3 protein, mouseSTAT3 Transcription FactorTyrosine

Identifiers

PMID17925034
PMCPMC2242666
OpenAlexW2088648946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.